The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Bifemelane     4-(2-benzylphenoxy)-N-methyl- butan-1-amine

Synonyms: Bifemelano, Bifemelanum, Tocris-0767, SureCN200583, MCI-2016, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Bifemelane


Psychiatry related information on Bifemelane


High impact information on Bifemelane

  • 4-(O-Benzylphenoxy)-N-methylbutylamine (Bifemelane, BP-N-methylbutylamine), a new psychotropic drug, was found to inhibit monoamine oxidase (MAO) in human brain synaptosomes [8].
  • Prolongation by bifemelane of potentiation of AP1 DNA binding in hippocampal CA1 subfield of gerbils with transient forebrain ischemia [1].
  • Limited proteolysis revealed that bifemelane induced expression of the AP1 consisting of constructive proteins different from those expressed in control animals in the CA1 subfield [1].
  • Bifemelane has an anti-amnesic effect, produces the translocation of protein kinase C in the hippocampal CA3 region but not in CA1 and enhances long-term potentiation in the mossy fibre-CA3 system but not in the Schaffer collateral-CA1 system [9].
  • Specific binding sites for bifemelane in the hippocampus of the guinea pig, relevant to its pharmacological actions [9].

Chemical compound and disease context of Bifemelane


Biological context of Bifemelane


Anatomical context of Bifemelane


Associations of Bifemelane with other chemical compounds


Gene context of Bifemelane


Analytical, diagnostic and therapeutic context of Bifemelane


  1. Prolongation by bifemelane of potentiation of AP1 DNA binding in hippocampal CA1 subfield of gerbils with transient forebrain ischemia. Yoneda, Y., Kuramoto, N., Azuma, Y., Inoue, K., Ogita, K., Mitani, A., Yanase, H., Masuda, S., Zhang, L., Kataoka, K. J. Neurosci. Res. (1998) [Pubmed]
  2. Comparison of the effects of bifemelane hydrochloride and indeloxazine hydrochloride on scopolamine hydrobromide-induced impairment in radial maze performance. Ogawa, N., Haba, K., Sora, Y.H., Higashida, A., Sato, H., Ogawa, S. Clinical therapeutics. (1988) [Pubmed]
  3. Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Nomoto, M., Irifune, M., Fukuzaki, K., Fukuda, T. Neurosci. Lett. (1994) [Pubmed]
  4. Therapeutic effect of bifemelane on unilateral cerebral ischemia in gerbils. Hata, R., Matsumoto, M., Kitagawa, K., Tagaya, M., Matsuyama, T., Sugita, M., Kamada, T. Life Sci. (1995) [Pubmed]
  5. Bifemelane hydrochloride protects against cytotoxicity of hydrogen peroxide on cultured rat neuroblastoma cell line. Miyazaki, I., Iwata-Ichikawa, E., Asanuma, M., Iida, M., Ogawa, N. Neurochem. Res. (1999) [Pubmed]
  6. Effects of bifemelane on discrimination learning of serotonergic-dysfunction rats. Nomura, M. Pharmacol. Biochem. Behav. (1992) [Pubmed]
  7. Potential antidepressive properties of amantadine, memantine and bifemelane. Moryl, E., Danysz, W., Quack, G. Pharmacol. Toxicol. (1993) [Pubmed]
  8. 4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. Naoi, M., Nomura, Y., Ishiki, R., Suzuki, H., Nagatsu, T. J. Neurochem. (1988) [Pubmed]
  9. Specific binding sites for bifemelane in the hippocampus of the guinea pig, relevant to its pharmacological actions. Fujii, T., Kuraishi, Y., Ueda, M., Satoh, M. Neuropharmacology (1991) [Pubmed]
  10. Chronic bifemelane hydrochloride administration enhances muscarinic cholinergic receptor binding in the senescent rat brain. Ogawa, N., Mizukawa, K., Haba, K., Asanuma, M., Mori, A. Journal of medicine. (1991) [Pubmed]
  11. Different drug-susceptibilities of long-term potentiation in three input systems to the CA3 region of the guinea pig hippocampus in vitro. Ishihara, K., Katsuki, H., Sugimura, M., Kaneko, S., Satoh, M. Neuropharmacology (1990) [Pubmed]
  12. Bifemelane in the treatment of central retinal artery or vein obstruction. Hirayama, Y., Matsunaga, N., Tashiro, J., Amemiya, T., Iwasaki, M. Clinical therapeutics. (1990) [Pubmed]
  13. Cognitive enhancers and hippocampal long-term potentiation in vitro. Kaneko, S., Maeda, T., Satoh, M. Behav. Brain Res. (1997) [Pubmed]
  14. Effects of several cerebroprotective drugs on NMDA channel function: evaluation using Xenopus oocytes and [3H]MK-801 binding. Kaneko, S., Sugimura, M., Inoue, T., Satoh, M. Eur. J. Pharmacol. (1991) [Pubmed]
  15. Impairment of hippocampal long-term potentiation following transient cerebral ischaemia in rat: effects of bifemelane, a potent inhibitor of ischaemia-induced acetylcholine release. Miyazaki, S., Katayama, Y., Furuichi, M., Kinoshita, K., Kawamata, T., Tsubokawa, T. Neurol. Res. (1993) [Pubmed]
  16. The use of Xenopus oocytes to evaluate drugs affecting brain Ca2+ channels: effects of bifemelane and several nootropic agents. Kaneko, S., Takahashi, H., Satoh, M. Eur. J. Pharmacol. (1990) [Pubmed]
  17. Bifemelane enhances high K(+)-evoked release of glutamate from mossy fiber synaptosomes of guinea-pig hippocampus. Ueda, M., Fujii, T., Kuraishi, Y., Satoh, M. Eur. J. Pharmacol. (1992) [Pubmed]
  18. Inhibitory effect of bifemelane on superoxide generation by activated neutrophils measured using a simple chemiluminescence method. Yoshida, T., Sotomatsu, A., Tanaka, M., Hirai, S. Free Radic. Res. (1994) [Pubmed]
  19. Different susceptibilities of long-term potentiations in CA3 and CA1 regions of guinea pig hippocampal slices to nootropic drugs. Satoh, M., Ishihara, K., Katsuki, H. Neurosci. Lett. (1988) [Pubmed]
  20. Effects of bifemelane on calcium and magnesium deposition in the central nervous system tissues of rats maintained on low-calcium diets. Yasui, M., Tsuda, T., Ota, K. J. Int. Med. Res. (1991) [Pubmed]
  21. Effects of bifemelane on the calcium level and ATP release of the human origin astrocyte clonal cell. Yoshida, Y., Kumagai, H., Ohkubo, Y., Tsuchiya, R., Morita, M., Miyakawa, H., Kudo, Y. J. Pharmacol. Sci. (2006) [Pubmed]
  22. Reduced choline acetyltransferase activity and muscarinic M1 receptor levels in aged Fisher 344 rat brains did not parallel their respective mRNA levels. Ogawa, N., Asanuma, M., Kondo, Y., Nishibayashi, S., Mori, A. Brain Res. (1994) [Pubmed]
  23. Tubulin and actin mRNAs in the young-adult and the aged rat brain: effects of repeated administration with bifemelane hydrochloride. Nishibayashi, S., Ogawa, N., Asanuma, M., Kondo, Y., Mori, A. Archives of gerontology and geriatrics. (1994) [Pubmed]
  24. Ischemia-induced changes in alpha-tubulin and beta-actin mRNA in the gerbil brain and effects of bifemelane hydrochloride. Asanuma, M., Ogawa, N., Hirata, H., Chou, H.H., Kondo, Y., Mori, A. Brain Res. (1993) [Pubmed]
  25. Effect of bifemelane hydrochloride on an injury of the liver caused by ischemia-reperfusion in rats. Nagai, T., Egashira, T., Yamanaka, Y. Jpn. J. Pharmacol. (1990) [Pubmed]
  26. Effects of bifemelane hydrochloride on cerebral circulation and metabolism in patients with aphasia. Kabasawa, H., Matsubara, M., Kamimoto, K., Hibino, H., Banno, T., Nagai, H. Clinical therapeutics. (1994) [Pubmed]
WikiGenes - Universities